Mersana therapeutics, inc. (MRSN)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
Cash flows from operating activities
Net income (loss)

-67,035

-28,208

-34,394

-34,671

-29,953

-64,257

-55,792

-46,455

-43,049

-38,707

0

0

0

Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation

1,156

1,245

1,313

1,345

1,336

1,257

1,162

1,055

977

928

0

0

0

Loss on disposal of fixed assets

-

-

-

-

-

-20

0

0

0

-

-

-

-

Net amortization of premiums and discounts on investments

292

222

95

57

135

296

0

0

0

-

-

-

-

Stock-based compensation

5,317

4,872

4,738

4,506

4,303

3,884

3,188

2,508

1,903

1,422

0

0

0

Non-cash rent expense

-

-

-

-

-

-

0

0

0

-

-

-

-

Change in deferred rent

-

-

-

-

-

-

-

-

-

-159

0

0

0

Other non-cash items

0

-

-

-

0

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Accounts receivable

-

-459

-288

-1,393

180

-325

-145

1,168

-424

-267

0

0

0

Prepaid expenses and other current assets

-1,460

-2,179

-1,007

256

215

1,690

788

2,244

1,777

1,200

0

0

0

Other assets

-

-

-

-

-

1,132

1,420

950

348

-60

0

0

0

Accounts payable

-2,359

-3,110

654

2,483

4,548

7,375

3,842

2,516

771

1,335

0

0

0

Accrued expenses

-2,234

-3,569

-2,655

2,360

2,217

5,431

5,998

3,871

1,724

3,562

0

0

0

Operating lease assets

0

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease liabilities

0

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-800

-41,381

-42,261

-42,727

-44,858

-6,243

-6,233

-9,498

-9,236

-9,894

0

0

0

Net cash used in operating activities

-64,303

-67,744

-71,072

-65,262

-62,513

-55,216

-50,308

-50,918

-49,159

-42,679

0

0

0

Cash flows from investing activities
Maturities of marketable securities

36,000

27,000

24,500

45,500

75,900

88,565

0

0

0

-

-

-

-

Purchase of property and equipment

298

605

882

1,128

1,475

1,370

1,803

1,635

939

1,143

0

0

0

Net cash provided by investing activities

-17,986

-27,293

-30,070

32,425

74,425

87,195

60,282

-2,299

-76,255

-99,624

0

0

0

Cash flows from financing activities
Net proceeds from offering of common stock

-

92,162

0

0

0

-

-

-

-

-

-

-

-

Proceeds from exercise of stock options

252

175

186

293

705

918

874

813

603

452

0

0

0

Payments from issuance of debt

0

-

-

-

-

-

-

-

-

-

-

-

-

Payments under capital lease obligations

0

-

-

-

-

-

-

-

-

-

-

-

-

Payments of financing costs

-

-

-

-

-

-

-

-

-

-

-

0

0

Net cash provided by (used in) financing activities

5,410

97,704

97,684

97,901

93,013

1,064

874

71,306

69,253

68,597

0

0

0

Increase (decrease) in cash, cash equivalents and restricted cash

-76,879

2,667

-3,458

65,064

104,925

33,043

10,848

18,089

-56,161

-73,706

0

0

0

Supplemental disclosures of non-cash activities:
Purchases of property and equipment in accounts payable and accrued expenses

-

-

-

109

23

317

0

0

0

-

-

-

0

Cash paid for interest

0

-

-

-

-

-

-

-

-

-

-

-

-

Right-of-use assets obtained in exchange for operating lease liabilities

0

-

-

-

0

-

-

-

-

-

-

-

-

Right-of-use assets obtained in exchange for financing lease liabilities

-

-

-

-

0

-

-

-

-

-

-

-

-

Adjustment to accumulated deficit and deferred revenue upon adoption of Topic 606

-

-

-

-

-

-2,031

0

0

0

-

-

-

-